Published in Mol Neurobiol on July 08, 2012
Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The "UP" Study | NCT03840005
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology (2015) 1.43
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03
The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob Adv Health Med (2014) 0.94
The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. Scientifica (Cairo) (2013) 0.89
TGFβ Contributes to the Anti-inflammatory Effects of Tauroursodeoxycholic Acid on an Animal Model of Acute Neuroinflammation. Mol Neurobiol (2016) 0.80
The therapeutic potential of chemical chaperones in protein folding diseases. Prion (2014) 0.79
Suppression of glia maturation factor expression prevents 1-methyl-4-phenylpyridinium (MPP⁺)-induced loss of mesencephalic dopaminergic neurons. Neuroscience (2014) 0.78
Obesity surgery: happy with less or eternally hungry? Trends Endocrinol Metab (2013) 0.78
Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease. J Virol (2015) 0.76
Critical Role of Endoplasmic Reticulum Stress in Chronic Intermittent Hypoxia-Induced Deficits in Synaptic Plasticity and Long-Term Memory. Antioxid Redox Signal (2015) 0.76
Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy. Acta Neuropathol (2016) 0.75
Protein Kinases and Parkinson's Disease. Int J Mol Sci (2016) 0.75
Bile Acids in Neurodegenerative Disorders. Front Aging Neurosci (2016) 0.75
Tauroursodeoxycholic acid reduces ER stress by regulating of Akt-dependent cellular prion protein. Sci Rep (2016) 0.75
Tauroursodeoxycholic acid: more than just a neuroprotective bile conjugate. Neural Regen Res (2017) 0.75
Regulation of JNK signaling by GSTp. EMBO J (1999) 4.06
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Effectiveness of a 'thrombolysis nurse' in shortening delay to thrombolysis in acute myocardial infarction. J R Coll Physicians Lond (1999) 3.35
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer (2010) 3.25
Risk of death in prisoners after release from jail. Aust N Z J Public Health (2004) 2.86
Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK) Eur Heart J (2000) 2.51
The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem Soc Trans (2000) 2.40
Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci U S A (1998) 2.32
Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis (1997) 2.05
Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature (1990) 1.96
Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM (2005) 1.94
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis (1993) 1.84
Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis (1997) 1.78
Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol (1994) 1.76
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut (2005) 1.73
Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics (1996) 1.67
Molecular mechanisms of drug resistance. Biochem J (1990) 1.56
Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther (2001) 1.56
Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis (2003) 1.54
Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis (1991) 1.53
A new component of bacteriophage Mu replicative transposition machinery: the Escherichia coli ClpX protein. Mol Microbiol (1994) 1.52
Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term followup study. Arthritis Rheum (1999) 1.52
Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc Natl Acad Sci U S A (1994) 1.51
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
An outbreak of multiresistant Acinetobacter baumanii in a university hospital in São Paulo, Brazil. Infect Control Hosp Epidemiol (1996) 1.50
CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics (1994) 1.50
Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages. Nucleic Acids Res (1989) 1.48
The human horizontal vestibulo-ocular reflex in response to high-acceleration stimulation before and after unilateral vestibular neurectomy. Exp Brain Res (1990) 1.48
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer (1987) 1.47
Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis (1988) 1.45
The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem (2001) 1.44
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J (1992) 1.44
Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards. Proc Natl Acad Sci U S A (1988) 1.43
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A (2000) 1.40
Raised cardiac troponin T levels in patients without acute coronary syndrome. Postgrad Med J (2007) 1.39
Msp-1 polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucleic Acids Res (1987) 1.37
Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis (1990) 1.28
Metabolic polymorphisms and cancer susceptibility. Cancer Surv (1995) 1.26
The reduction of polyhalogenated methanes by liver microsomal cytochrome P450. Mol Pharmacol (1977) 1.25
Human microsomal glutathione S-transferase. Its involvement in the conjugation of hexachlorobuta-1,3-diene with glutathione. Biochem J (1989) 1.24
Diagnosis of acute appendicitis: value of unenhanced CT. AJR Am J Roentgenol (1993) 1.24
Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia (2011) 1.23
The role of glutathione-dependent enzymes in drug resistance. Pharmacol Ther (1991) 1.21
First observation of CP violation in the decays of B(s)0 mesons. Phys Rev Lett (2013) 1.21
Characterization, localization and regulation of a novel phenobarbital-inducible form of cytochrome P450, compared with three further P450-isoenzymes, NADPH P450-reductase, glutathione transferases and microsomal epoxide hydrolase. Carcinogenesis (1984) 1.20
Cloning and characterization of a novel human dual flavin reductase. J Biol Chem (2000) 1.18
Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc Natl Acad Sci U S A (1990) 1.16
Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem J (1990) 1.16
Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J (1990) 1.14
Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci (1996) 1.14
Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys (1989) 1.13
Multiple forms of cytochrome P-450 related to forms induced marginally by phenobarbital. Differences in structure and in the metabolism of alkoxyresorufins. Biochem J (1986) 1.13
Stopped-flow kinetic studies of flavin reduction in human cytochrome P450 reductase and its component domains. Biochemistry (2001) 1.13
Progression of collagenous colitis to ulcerative colitis. J Clin Gastroenterol (2001) 1.11
Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution. Protein Sci (1999) 1.10
Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics (2000) 1.10
Detection of debrisoquine hydroxylation phenotypes. Lancet (1990) 1.09
Aflatoxin, liver enzymes, and hepatitis B virus infection in Gambian children. Cancer Epidemiol Biomarkers Prev (1994) 1.08
A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry (1996) 1.08
Starvation-induced Mucts62-mediated coding sequence fusion: a role for ClpXP, Lon, RpoS and Crp. Mol Microbiol (1999) 1.08
Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol (1993) 1.06
Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells. J Biol Chem (1994) 1.05
Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol (2009) 1.05
Monte Carlo modelling of an extended DXA technique. Phys Med Biol (1998) 1.04
Pi-class glutathione S-transferase: regulation and function. Chem Biol Interact (1998) 1.04
Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics (1999) 1.03
Glutathione S-transferase subunits in the mouse and their catalytic activities towards reactive electrophiles. Arch Toxicol Suppl (1987) 1.03
Identification of human cytochromes P-450 analogous to forms induced by phenobarbital and 3-methylcholanthrene in the rat. Biochem J (1985) 1.03
Isolation and characterization of two mouse Pi-class glutathione S-transferase genes. Biochem J (1994) 1.03
Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem (1996) 1.03
Regulation of phenobarbital-inducible cytochrome P-450s in rat and mouse liver following dexamethasone administration and hypophysectomy. Biochem J (1988) 1.03
High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinog (1993) 1.02
Xenobiotic metabolizing enzymes are not restricted to parenchymal cells in rat liver. Mol Pharmacol (1987) 1.01
The localization of equivalent dipoles of EEG sources by the application of electrical field theory. Electroencephalogr Clin Neurophysiol (1975) 1.00
Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts. Cancer Res (1986) 1.00
Glutathione S-transferase isoenzymes and glutathione peroxidase activity in normal and tumour samples from human lung. Carcinogenesis (1988) 1.00
Deduced amino acid sequence, gene structure and chromosomal location of a novel human class Mu glutathione S-transferase, GSTM4. Biochem J (1993) 0.99
Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J (2008) 0.99
Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis (1990) 0.99
Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer (1994) 0.99
Cytochrome p-450: localization in rabbit lung. Science (1980) 0.98
Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity. Cancer Res (1987) 0.98
A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis (1991) 0.98
The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol (1992) 0.98
Pyogenic arthritis of the sacro-iliac joint. Long-term follow-up. J Bone Joint Surg Am (1976) 0.98
1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene, an extremely potent modulator of mouse hepatic cytochrome P-450 gene expression. Biochem J (1993) 0.98
A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet (1997) 0.97
Characterization of the free radical formed in aerobic microsomal incubations containing carbon tetrachloride and NADPH. Biochem Biophys Res Commun (1979) 0.97
Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol (2000) 0.97